FMP
Milestone Pharmaceuticals Inc.
MIST
NASDAQ
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
1.34 USD
0.105 (7.87%)
Historical Prices
From:
To:
About
ceo
Mr. Joseph G. Oliveto M.B.A.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
CIK
0001408443
ISIN
CA59935V1076
CUSIP
59935V107
Address
1111 Dr. Frederik-Philips Boul...
Phone
15143360444
Country
CA
Employee
33
IPO Date
May 9, 2019
Financial Statement
Earnings
MIST Financial Summary
CIK
0001408443
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
59935V107
ISIN
CA59935V1076
Country
CA
Price
1.33
Beta
1.38
Volume Avg.
2.55M
Market Cap
71.23M
Shares
-
52-Week
0.625-2.75
DCF
-0.47
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.99
P/B
-
Website
https://www.milestonepharma.com
Upgrades and Downgrades
Rating Distribution
TheFly
a month ago
Apr 1, 2025
Buy
Hold
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MIST News
Rayan Ahmad
Mar 28, 2025
Recent Market Movements: Analysis of Top Losers
In recent market movements, several companies have experienced significant price changes, reflecting various underlying factors that have influenced their stock performance. Here's a consolidated analysis of the top losers in the market, focusing on their price movements, relevant events, and key developments. Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw a dramatic decrease in its stock price, dropping by approximately 59.56% to $0.9098. This significant movement is attributed to the U.S. F...
24/7 Wall Street
Aug 8, 2024
4 Stocks Under $5 To Buy Now
Are you looking for stocks to buy with low price tags?
GlobeNewsWire
May 31, 2024
Milestone® Pharmaceuticals to Participate in the Upcoming Je...
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024.
Zacks Investment Research
May 16, 2024
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Wha...
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlobeNewsWire
Apr 17, 2024
Milestone® Pharmaceuticals to Present Data on Etripamil at t...
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at https://MilestonePh...
GlobeNewsWire
Apr 1, 2024
Milestone® Pharmaceuticals to Present Data on Etripamil at t...
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24), to be held April 6-8th in Atlanta, Georgia, and ...
Zacks Investment Research
Jan 16, 2024
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceutical...
Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Research
Dec 27, 2023
Milestone Pharma (MIST) Down on Regulatory Update for Etripa...
Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.
